Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 Australian Biotech
Latest Video
New Stories
-
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News -
AI screening tool gives pathologists 'super' vision to detect hidden cancer
May 7, 2026 - - Latest News -
Australian company celebrated in centenary project on royal and parliamentary leadership
May 6, 2026 - - Latest News -
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News
